title: Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
abstract: BACKGROUND
  Polypoidal choroidal vasculopathy (PCV) is characterized by the presence of polyps with or without a branching vascular network and more prevalent among Asians. The aim of this study was to compare the outcomes of conbercept therapy between two different angiographic subtypes of PCV.
  
  
  METHODS
  Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In Type 1, both feeder and draining vessels are visible on ICGA and network vessels are numerous. In Type 2, neither feeder nor draining vessels are detectable, and the number of network vessels is small. The patients were treated with intravitreal conbercept (IVC) for 3 months. Additional IVC was given at subsequent monthly visits, if needed. The patients were followed up for 12 months, and changes in mean best-corrected visual acuity (BCVA), central retinal thickness (CRT), subretinal fluid (SRF) thickness, pigmented epithelial detachment (PED), hemorrhage, and number of polypoidal lesions were evaluated.
  
  
  RESULTS
  The mean BCVA in Type 2 PCV (15.92 ± 9.76 letters) achieved a significantly greater improvement than that in the Type 1 (14.10 ± 9.07 letters) at month 12 (t = 2.37, P< 0.01). Moreover, the mean CRT decrease was numerically greater in Type 2 (120.44 ± 73.81 μm) compared with Type 1 (106.48 ± 72.33 μm) at month 6 (t = 4.31, P< 0.01), and greater in Type 2 (130.21 ± 76.28 μm) compared with Type 1 (111.67 ± 79.57 μm) at month 9 (t = 1.87, P< 0.01). There was no significant difference between the two types for the decrease in SRF thickness, PED height, and regression of polyps from month 3 to 12 (t = 2.97, P > 0.05).
  
  
  CONCLUSIONS
  Classification systems for PCV will show differences in presentation, natural history, or response to anti-vascular endothelial growth factor treatment and might, therefore, provide a new key to the choice of treatment for the disease.
authors: Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors: Yong
authors: Y
authors: Cheng
authors: Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors: Xuan
authors: X
authors: Shi
authors: Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors: Jin-Feng
authors: JF
authors: Qu
authors: Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors: Ming-Wei
authors: MW
authors: Zhao
authors: Department of Ophthalmology, Peking University People's Hospital, Beijing 100044; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100044; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors: Xiao-Xin
authors: XX
authors: Li
mesh_terms: D000368:Aged; D002829:Choroid / Q000503:physiopathology / Q000601:surgery*; D020256:Choroidal Neovascularization / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology